Standing up in public for a broader conception of value in healthcare.

25-32 of 74 News

viewpoint 4/27/17

On the Health Affairs Blog: Lakdawalla, Sachs, and Bagley Focus on Medicaid’s Best-Price Rule and Trump Administration Opportunity to Advance Value-Based Pricing IVI’s Darius Lakdawalla, along with Rachel Sachs and Nicholas Bagley, examine how Medicaid’s best-price rule complicates the development of value-based pricing, and suggest a potential solution that could come out of new Trump administration CMS policies. READ MORE

viewpoint 4/24/17

On the Health Affairs Blog: Sood, Buckley and Strom Present a Win-Win Strategy for Improving Access to Hepatitis C Medicines Neeraj Sood, Gillian Buckley, and Brian Strom present a strategy to improve patient access to Hepatitis C medicines by having pharma patent holders license their patents to the federal government. READ MORE

viewpoint 4/14/17

In Health Affairs: Balancing the Use of Cost-Effectiveness Analysis in Healthcare Innovations IVI's Peter Neumann and James Baumgardner examine the reasons why the application of CEA technologies across different types of healthcare interventions are imbalanced, and suggest some possible ways in which the policies of government and private entities might change to address the issue. READ MORE

viewpoint 4/12/17

On the Health Affairs Blog: Assessing the Value of Treatments for Rare Diseases Presents Several Unique Challenges IVI's Darius Lakdawalla and Anupam Jena argue it's essential that value frameworks consider the potentially unique aspects of value that rare disease treatments provide. READ MORE

viewpoint 4/07/17

On the Health Affairs Blog: Rachel Sachs Summarizes Scott Gottlieb's FDA Commissioner Confirmation Hearing Calling it "remarkably unremarkable," Rachel Sachs summarizes Scott Gottlieb's recent FDA Commissioner confirmation hearing. READ MORE

viewpoint 4/05/17

On the Health Affairs Blog: Silver Suggests Patent Buyouts and Licensing Changes As Strategy For Lowering Brand Drug Prices Jonathan Silver examines patent buyouts and licensing as a novel strategy for lowering branded drug prices. READ MORE

viewpoint 4/03/17

On the Health Affairs Blog: Fox and Watrous Cite Lessons Learned from Genentech-Priority Health Pilot in Illustrating Outcomes-Based Contracting Challenges John Fox and Marc Watrous use the 2015' Genentech-Priority Health Pilot as a case study in the challenges presented in outcomes-based contracting. READ MORE

viewpoint 4/03/17

On the Health Affairs Blog: Blumenthal, Linthicum and Kamal-Bahl Address Outcomes-Based Pricing Agreements Daniel Blumenthal, Mark Linthicum, and Sachin Kamal-Bahl outline the key challenges and strategies surrounding the establishment of outcomes-based pricing agreements. READ MORE